Richard T Eastman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8894957/publications.pdf

Version: 2024-02-01

44 papers	3,638 citations	201674 27 h-index	233421 45 g-index
54 all docs	54 docs citations	54 times ranked	5810 citing authors

#	Article	IF	Citations
1	A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model. PLoS ONE, 2022, 17, e0261821.	2.5	6
2	Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents. ACS Pharmacology and Translational Science, 2022, 5, 468-478.	4.9	3
3	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. Molecular Therapy, 2021, 29, 873-885.	8.2	78
4	Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts. Journal of Medicinal Chemistry, 2021, 64, 2291-2309.	6.4	11
5	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127906.	2.2	15
6	Deep learning identifies synergistic drug combinations for treating COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	87
7	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31365-31375.	7.1	27
8	Targeting ACE2â€“RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. ACS Pharmacology and Translational Science, 2020, 3, 1352-1360.	4.9	60
9	Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype. ACS Pharmacology and Translational Science, 2020, 3, 1144-1157.	4.9	8
10	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science, 2020, 6, 672-683.	11.3	684
11	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	3.5	69
12	Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nature Communications, 2019, 10, 4300.	12.8	35
13	New WS9326A Derivatives and One New Annimycin Derivative with Antimalarial Activity are Produced by Streptomyces asterosporus DSM 41452 and Its Mutant. ChemBioChem, 2018, 19, 272-279.	2.6	25
14	Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12513-12518.	7.1	46
15	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	11.3	32
16	Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel Structures. Frontiers in Pharmacology, 2018, 9, 1096.	3.5	27
17	A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria. Malaria Journal, 2018, 17, 160.	2.3	19
18	Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1718-1721.	1.4	1

#	Article	IF	Citations
19	PfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockers. Scientific Reports, 2016, 6, 25379.	3.3	15
20	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Scientific Reports, 2015, 5, 13891.	3.3	92
21	Regulation of Plasmodium yoelii Oocyst Development by Strain- and Stage-Specific Small-Subunit rRNA. MBio, 2015, 6, e00117.	4.1	11
22	Actinoramide A Identified as a Potent Antimalarial from Titration-Based Screening of Marine Natural Product Extracts. Journal of Natural Products, 2015, 78, 2411-2422.	3.0	30
23	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. Journal of Infectious Diseases, 2014, 209, 275-284.	4.0	83
24	Supergenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. Cell, 2014, 158, 916-928.	28.9	113
25	Ex Vivo Susceptibility of Plasmodium falciparum to Antimalarial Drugs in Western, Northern, and Eastern Cambodia, 2011-2012: Association with Molecular Markers. Antimicrobial Agents and Chemotherapy, 2013, 57, 5277-5283.	3.2	34
26	A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission. Antimicrobial Agents and Chemotherapy, 2013, 57, 425-435.	3.2	32
27	Genomeâ€wide profiling of chromosome interactions in <scp>P</scp>lasmodium falciparum characterizes nuclear architecture and reconfigurations associated with antigenic variation. Molecular Microbiology, 2013, 90, 519-537.	2.5	48
28	Drugâ€resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters, 2011, 585, 1551-1562.	2.8	222
29	Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured Plasmodium falciparum Parasites. Antimicrobial Agents and Chemotherapy, 2011, 55, 3908-3916.	3.2	102
30	Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1214-23.	7.1	293
31	Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Reviews Microbiology, 2009, 7, 864-874.	28.6	440
32	Recent highlights in antimalarial drug resistance and chemotherapy research. Trends in Parasitology, 2008, 24, 537-544.	3.3	80
33	Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Molecular and Biochemical Parasitology, 2007, 152, 66-71.	1.1	28
34	C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Molecular and Biochemical Parasitology, 2007, 153, 115-124.	1.1	25
35	Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation. Journal of Lipid Research, 2006, 47, 233-240.	4.2	104
36	Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum. Journal of Biological Chemistry, 2005, 280, 13554-13559.	3.4	66

#	Article	IF	Citations
37	Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Current Opinion in Investigational Drugs, 2005, 6, 791-7.	2.3	33
38	The Candida albicans Lanosterol 14-Î±-Demethylase (ERG11) Gene Promoter Is Maximally Induced after Prolonged Growth with Antifungal Drugs. Antimicrobial Agents and Chemotherapy, 2004, 48, 1136-1144.	3.2	56
39	Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents. Journal of Medicinal Chemistry, 2004, 47, 432-445.	6.4	49
40	Cloning and analysis of Trypanosoma cruzi lanosterol 14Î±-demethylase. Molecular and Biochemical Parasitology, 2003, 132, 75-81.	1.1	18
41	Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology, 2003, 126, 155-163.	1.1	126
42	Oxidosqualene Cyclase Inhibitors as Antimicrobial Agents. Journal of Medicinal Chemistry, 2003, 46, 4240-4243.	6.4	33
43	Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen) Tj ETQq1 1 0.784314 rgBT /Ove	3.2	77
44	Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Molecular and Biochemical Parasitology, 2002, 122, 181-188.	1.1	53